Literature DB >> 29212621

Stenotic Lesions and the Maximum Diameter of Coronary Artery Aneurysms in Kawasaki Disease.

Etsuko Tsuda1, Nobuyuki Tsujii2, Yohsuke Hayama2.   

Abstract

OBJECTIVES: To determine the prevalence of subsequent stenotic lesions based on the maximum diameter of the largest coronary artery aneurysm in patients with Kawasaki disease and the threshold value of coronary artery diameter associated with risk of developing stenotic lesion. STUDY
DESIGN: There were 214 patients (160 males) who had at least 1 aneurysm in a selective coronary angiogram (CAG) done <100 days after the onset of Kawasaki disease were studied. We measured the maximal coronary artery aneurysm diameter in 3 major branches in the initial CAGs. Branches were classified into 3 groups according to their maximal coronary artery aneurysm diameter: large, ≥8.0 mm; medium, ≥6.0 mm but <8.0 mm; and small, <6.0 mm. Subsequent CAGs were performed in the late follow-up period. We investigated the stenotic lesion in the follow-up CAGs, and evaluated the prevalence of stenotic lesion in each group based on body surface area (BSA) by the Kaplan-Meier method. Localized stenosis of ≥25% and complete occlusion were included as stenotic lesion in this study. We also determined the cutoff point for stenotic lesion.
RESULTS: The median interval from the initial CAGs to the latest CAG was 8 years, with a maximum of 32 years. For a BSA of <0.50 m2, the 20-year prevalence of large and medium stenotic lesions was 78% (n = 62; 95% CI, 63-89) and 81% (n = 40; 95% CI, 63-89), respectively. For a BSA of ≥0.50 m2, large and medium stenotic lesions were 82% (n = 75; 95% CI, 67-91) and 40% (n = 56; 95% CI, 20-64), respectively (P < .0001).
CONCLUSION: The cutoff points of the coronary artery diameter within the first 100 days after the onset of Kawasaki disease leading to a stenotic lesion in the late period, were a diameter of ≥6.1 mm with a BSA of <0.50 m2 and a diameter of ≥8.0 mm with a BSA of ≥0.50 m2. Those cutoff points would have corresponded with a Z score of at least 10 on 2-dimensional echocardiography. Careful follow-up and antithrombotic therapy should be provided to patients who meet these criteria.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Kawasaki disease; coronary artery aneurysm; coronary artery revascularization; localized stenosis; stenotic lesions

Mesh:

Year:  2017        PMID: 29212621     DOI: 10.1016/j.jpeds.2017.09.077

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  8 in total

1.  Oxidised Low-Density Lipoprotein and Its Receptor-Mediated Endothelial Dysfunction Are Associated with Coronary Artery Lesions in Kawasaki Disease.

Authors:  Yue-E He; Hui-Xian Qiu; Rong-Zhou Wu; Xing Rong; Hai-Tang Xu; Ru-Lian Xiang; Mao-Ping Chu
Journal:  J Cardiovasc Transl Res       Date:  2019-08-19       Impact factor: 4.132

2.  Magnetocardiographic recognition of abnormal depolarization and repolarization in patients with coronary artery lesions caused by Kawasaki disease.

Authors:  Wataru Tamaki; Etsuko Tsuda; Syuji Hashimoto; Tamami Toyomasa; Mikiya Fujieda
Journal:  Heart Vessels       Date:  2019-03-25       Impact factor: 2.037

Review 3.  COVID-19 in Children.

Authors:  Meena Kalyanaraman; Michael R Anderson
Journal:  Pediatr Clin North Am       Date:  2022-02-02       Impact factor: 3.580

4.  American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2.

Authors:  Lauren A Henderson; Scott W Canna; Kevin G Friedman; Mark Gorelik; Sivia K Lapidus; Hamid Bassiri; Edward M Behrens; Anne Ferris; Kate F Kernan; Grant S Schulert; Philip Seo; Mary Beth F Son; Adriana H Tremoulet; Rae S M Yeung; Amy S Mudano; Amy S Turner; David R Karp; Jay J Mehta
Journal:  Arthritis Rheumatol       Date:  2021-02-15       Impact factor: 10.995

5.  Falling Through the Cracks: The Current Gap in the Health Care Transition of Patients With Kawasaki Disease: A Scientific Statement From the American Heart Association.

Authors:  Nagib Dahdah; Samuel C Kung; Kevin G Friedman; Ariane Marelli; John B Gordon; Ermias D Belay; Annette L Baker; Dhruv S Kazi; Patience H White; Adriana H Tremoulet
Journal:  J Am Heart Assoc       Date:  2021-10-11       Impact factor: 5.501

Review 6.  Should We Be Screening for Ischaemic Heart Disease Earlier in Childhood?

Authors:  Pier Paolo Bassareo; Stephen T O'Brien; Esme Dunne; Sophie Duignan; Eliana Martino; Francesco Martino; Colin J Mcmahon
Journal:  Children (Basel)       Date:  2022-06-30

7.  American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1.

Authors:  Lauren A Henderson; Scott W Canna; Kevin G Friedman; Mark Gorelik; Sivia K Lapidus; Hamid Bassiri; Edward M Behrens; Anne Ferris; Kate F Kernan; Grant S Schulert; Philip Seo; Mary Beth F Son; Adriana H Tremoulet; Rae S M Yeung; Amy S Mudano; Amy S Turner; David R Karp; Jay J Mehta
Journal:  Arthritis Rheumatol       Date:  2020-10-03       Impact factor: 15.483

8.  American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3.

Authors:  Lauren A Henderson; Scott W Canna; Kevin G Friedman; Mark Gorelik; Sivia K Lapidus; Hamid Bassiri; Edward M Behrens; Kate F Kernan; Grant S Schulert; Philip Seo; Mary Beth F Son; Adriana H Tremoulet; Christina VanderPluym; Rae S M Yeung; Amy S Mudano; Amy S Turner; David R Karp; Jay J Mehta
Journal:  Arthritis Rheumatol       Date:  2022-02-03       Impact factor: 15.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.